Loading cancer entity…
Loading cancer entity…
Clinical trials
62 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05785052 | Biomarkers of Renal Cancer(BRC) | unknown | — | 1,000 | Biorek S.R.L.INDUSTRY | 2 | Mar 27, 2023 | clinicaltrials |
| NCT05625919 | A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa) | unknown | Phase 1 / Phase 2 | 54 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 28, 2022 |
| clinicaltrials |
| NCT05617105 | Molecular Characterization of Perivascular Epithelioid Cell Tumors(PEComesCells) | unknown | — | 100 | University Hospital, Strasbourg, FranceOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT05190627 | Effect of Loratadine in Lymphangioleiomyomatosis(LORALAM) | unknown | Phase 2 | 62 | Institut d'Investigació Biomèdica de BellvitgeOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05087134 | Characterizing LAM With 11C-Choline PET/CT | unknown | Early Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | Oct 21, 2021 | clinicaltrials |
| NCT04577937 | Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis | unknown | N/A | 15 | dr. Stefano NavaOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT03916575 | PEComas: Natural History and Prognostic Factors(PEComas) | unknown | — | 60 | University Hospital, Strasbourg, FranceOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT00490789 | Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM(TESSTAL) | unknown | Phase 2 | 14 | Cardiff UniversityOTHER | 1 | Apr 30, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Mar 27, 2023source: clinicaltrials